Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategy TEL AVIV, Israel and SHANGHAI,...
American Migraine Foundation Highlights HeadaTerm2 in Its Latest Device Recommendations, Backed by Clinical Evidence
VANCOUVER, BC, June 16, 2025 /PRNewswire/ -- WAT Medical Enterprise Ltd. is pleased to announce that its migraine relief device, HeadaTerm 2, is now featured on the American Migraine Foundation's (AMF) updated Device Corner, a patient education resource highlighting FDA-cleared neuromodulation devices for migraine treatment. HeadaTerm 2 is a non-invasive, drug-free device designed to help manage...
China National Intellectual Property Administration Affirms Validity of Harbour BioMed’s Patent; Infringement Lawsuit Moves Forward
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, June 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced key developments in its intellectual property (IP) protection efforts. Following an invalidation request filed by Biocytogen Pharmaceuticals (Beijing) Co.,...
BioDlink’s Bevacizumab Approved for Market Launch in Nigeria, Accelerating Global Expansion
BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), following GMP certifications in Brazil (a PIC/S member), Colombia, Egypt, Indonesia, and Argentina—further strengthening its global presence by opening access to the African market. Backed by a global recognized quality...
“Luminous Path, Shared Stride – Brazil and China”
SHANGHAI, June 16, 2025 /PRNewswire/ -- Brazil's HIHUB.TECH delegation embarked on a landmark visit to Shanghai, exploring cutting-edge advancements in healthcare and aesthetic medicine. The delegation's first stop was Zhongshan Hospital, a world-renowned medical institution consistently ranked among China's top three hospitals. As a pioneer in robotic surgery and organ transplantation, the 1800-bed facility boasts 46 national key disciplines...
Flat Medical Partners with Mercury Medical for US Distribution of EpiFaith Smart Syringe
Strategic Partnership Brings Breakthrough Epidural Safety Technology to US Anesthesia Market AUSTIN, Texas, June 16, 2025 /PRNewswire/ -- Flat Medical, a pioneering medtech company specializing in innovative safety solutions for anesthesia and pain medicine, today announced it has signed a dealership agreement with Mercury Medical for the distribution of the EpiFaith Smart Syringe in the US anesthesia market. The...
WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors
SHANGHAI, June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been recognized among the Top 10 "Most Honored Companies" in new rankings from Extel (formerly known as Institutional Investor). WuXi AppTec was chosen from more than 1,600...
NUZ-001 Shows Promise in Zebrafish Model of Huntington’s Disease
Highlights: NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease Treatment prevented hallmark developmental and morphological abnormalities, protected against neuronal cell death, restored delayed haemoglobin production, and rescued BDNF expression following Htt protein knockdown Neurizon plans to initiate additional validation studies in mammalian...
PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIAL
HIGHLIGHTS A confirmed pathological complete response has been recorded in the ACCENT trial A pathological complete response (pCR) is extremely rare in patients undergoing treatment for advanced pancreatic cancer A pCR means that there are no signs of cancer in tissue examined by a pathologist following surgical removal The ACCENT trial is evaluating the Company's best-in-class FAK inhibitor...
8th Asia Dengue Summit Renews Call to Achieve Zero Dengue Deaths, with a Record 14 million Global Cases Reported in 2024
Health leaders, researchers, and advocates unite to advance efforts against dengue through innovation, prevention, and cross-sector collaboration. MANILA, Philippines, June 16, 2025 /PRNewswire/ -- As dengue cases in 2024 double to over 14 million globally, with Asia accounting for 70% of the global burden in 2024, the Asia Dengue Voice and Action (ADVA) Group reinforces the...
